PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Biotrial

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Biotrial's Top Executives to Speak at 3rd AGAH/Club Phase I Joint Annual Meeting - The two-day conference (April 28-29) will elaborate on the major theme of: “Managing Challenges in Early Drug Development: Biologicals and Small Molecules”. It will take place in Lyon, France
Biotrial's Top Executives to Speak at 3rd AGAH/Club Phase I Joint Annual Meeting

 

NewswireToday - /newswire/ - Rennes, Ille-et-Vilaine, France, 2009/04/23 - The two-day conference (April 28-29) will elaborate on the major theme of: “Managing Challenges in Early Drug Development: Biologicals and Small Molecules”. It will take place in Lyon, France.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

This conference organized by the AGAH (Association for Applied Human Pharmacology)/Club Phase I (Association of early compound development professionals) aims to provide an indispensable European forum for scientific experts in the field of pharmacology.

This meeting will address how sponsors, investigators, regulatory authorities and ethics committees are adapting to the new challenges raised by the first administration of a new compound to man. It will bring together over 250 professionals from varied backgrounds, companies and countries.

A number of pharmaceutical and biotech senior executives from all over Europe are expecting to attend the event, including specialists from Abbott, Aepodia, Bayer Schering, Boehringer Ingelheim, Evotec, Galderma, GSK, Merck Serono, Nycomed, Sanofi-Aventis, UCB and Wyeth.

More than 15 Biotrial key staff will be attending this event including: Jean-Marc Gandon Biotrial CEO, Alain Patat VP of Medical and Scientific Affairs, and Didier Chassard Associate Medical and Scientific Director. Within the ambitious and unique agenda planned for this conference Biotrial executives will be speaking on various topics such as: “Accreditation of phase I units in France”, “Stopping criteria in first-in-man studies”, “Update on the design of studies of drug-drug interaction with special focus on transporters”.

“As the president of Club Phase I, I am particularly proud and excited that Biotrial is such an active participant to this key conference,” stated Alain Patat, Biotrial’s VP of Medical and Scientific Affairs. “The benefits of such an event last well beyond the two-day conference. It is a place of highly rich intellectual exchange and a time when we can get to know our customers and market better.”

Jean-Marc Gandon, Biotrial’s CEO, added: “We are looking forward to participating and attending this important conference, which addresses pertinent topics developed by top European experts in the field of early compound development. It is a great opportunity to learn about recent advances in the field of early clinical research. As a CRO it is also key for Biotrial to understand how our market evolved to continuously adapt to its needs.”

Biotrial will be exhibiting at booth number S5.

About Biotrial
Founded in 1989 by Jean-Marc Gandon, PharmD, (President & CEO), Biotrial (biotrial.com) is an independent and privately owned CRO focusing mainly on early drug discovery and development services.

With 150 beds and a staff of 250 in several subsidiaries in France and the UK, Biotrial runs over 80 studies per year, either in their own clinics in Paris and Rennes, or in cooperation with hospital specialists and general practitioners.

With a large range of services from Phase I studies, Clinical Trial Management Phase II-IV, Oncology, Data Management, Biostatistics, Central Labs (ECG, Imaging), Medical Writing, Non-Clinical Pharmacology, QA & advice in Regulatory Affairs, Biotrial can manage every step of your development process.

About Club Phase I
Club Phase I is a French association, with all members involved in the field of early compound development (Industry, CRO, Hospitals-Universities). Since 1993, it provides a unique place where professionals can exchange – while keeping confidentiality obligations – scientific, methodological, and regulatory point of views and experiences.

About AGAH
The Association for Applied Human Pharmacology (AGAH) is a scientific medical non-profit organization which members work in the field of explorative drug development and human pharmacology. The organization is particularly open for professionals who work in the field of translational medicine (i.e. bringing new medicinal products from the bench into clinical research).

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Biotrial

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Biotrial's Top Executives to Speak at 3rd AGAH/Club Phase I Joint Annual Meeting

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Anne Peron - Biotrial.com 
+33(0)2 99 59 91 91 anne.peron[.]biotrial.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Biotrial securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Biotrial / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

Greenphire Sponsors Second Annual Clinical Trial Agreements, Investigator Payments and Fair Market Value Meeting
Genentech’s Gazyva Helped People with Previously Untreated Follicular Lymphoma Live Significantly Longer
BD Announces Adoption of Windows 10 ‘Internet of Things’ for the Pyxis™ ES System
Greenphire Named to Deloitte 2016 Technology Fast 500™
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin
MDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections
Greenphire Receives EU-US Privacy Shield Certification
The 2016 Georges Mathé Prize Recognizes Research on the Immunological Determinants of the Response to Breast Cancer Treatment
MDxHealth Announces Agreement with HIFU CLINIC Prostate Cancer Center for Distribution of SelectMDx in Poland
First Patient in Malaysia Receives TheraSphere™ Radioembolisation Therapy
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) Prefilled Syringe
BTG and Mirada Medical Announce CE Mark Certification for Simplicit90Y Dosimetry Software in Europe

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  Triggr & Bloom

Visit  BizJobs.com





 
  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)